Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Experts Update Antithrombotic Advice in AF Patients Undergoing PCI

News Daily News

Experts Update Antithrombotic Advice in AF Patients Undergoing PCI

February 09, 2021

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

News Daily News

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

December 22, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

March 16, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

News Daily News

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

December 19, 2019

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

December 02, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

New Review Probes Possibility of CVD Prevention Without Aspirin

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

April 24, 2018

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.